Introduction
were developed exhibited decreased virulence properties in mice (Smee et al., 2002b) . During those investigations the Copenhagen strain of vaccinia virus was also made resistant to cidofovir; it was additionally sensitive to HPMPA. Because wild-type (WT) Copenhagen virus is attenuated in mice, it was not possible to develop a mouse-virulent CDV-R form of that virus.
Later we developed the WT WR strain of vaccinia virus into a highly lethal respiratory infection model in mice for studying antiviral substances (Smee et al., 2001a,b) . This virus, on an infectious particle basis, is more virulent than cowpox virus in these animals and induces a more rapid onset to death. Thus, it was hypothesized that a CDV-R form of vaccinia (WR strain) virus would also be virulent to mice, assuming a CDV-R virus could be developed. Virulence would probably be decreased relative to WT virus, based upon what occurred with CDV-R cowpox virus (Smee et al., 2002b) . The objectives of the present investigation were to develop such a CDV-R vaccinia (WR strain) virus by cell culture passage, determine its susceptibility to related and unrelated anti-orthopoxvirus agents, determine its growth characteristics in cell culture and assess virulence properties of the virus in infected mice. The animal model could then be used to assess various antiviral agents against a CDV-R vaccinia virus infection.
Materials and methods

Antiviral compounds
Cidofovir was kindly provided by Dr M Hitchcock of Gilead Sciences (Foster City, CA, USA). HPMPA and HPMPG were synthesized at the Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic. HDP-cidofovir was prepared at the Department of Medicine, San Diego VA Healthcare System and the University of California at San Diego (La Jolla, CA, USA). S2242 and its orally active diacetyl ester prodrug form (HOE961) (Neyts & De Clercq, 2001) were kindly provided by Juergen Puenter of Aventis Pharma (Frankfurt, Germany). Ribavirin and ara-A were obtained from ICN Pharmaceuticals (Costa Mesa, CA, USA). The compounds were dissolved in cell culture medium for in vitro studies. Sterile saline and water were used for dissolving or suspending (in the case of ara-A) compounds for intraperitoneal (ip) or oral gavage (po) treatment of animals, respectively. The selected compounds represent different classes of antiviral agents, such as those inhibiting viral DNA synthesis (cidofovir, HPMPA, HPMPG, S2242, and ara-A) (Coen et al., 1982; Neyts et al., 1994; Andrei et al., 2000) , and ribavirin that inhibits vaccinia virus mRNA capping (Goswami et al., 1979) and the cellular enzyme inosine monophosphate dehydrogenase (Streeter et al., 1973; Smee et al., 2001c) . HDP-cidofovir is an orally active prodrug form of cidofovir (Quenelle et al., 2004; that exhibits greater potency than the parent compound against pox virus replication in cell culture (Keith et al., 2004) . Cyclophosphamide, an immunosuppressive agent, was purchased from Sigma (St Louis, MO, USA).
Virus and cells
Vaccinia virus (WR strain) was obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). The virus was initially propagated in African green monkey kidney (Vero) cells (ATCC). Higher virus titre for infection of animals was prepared in a second line of African green monkey kidney (MA-104) cells, purchased from BioWhittaker (Walkersville, MD, USA). Some viral assays were performed in mouse mammary tumour (C127I) cells (ATCC) in order to determine the extent of virus replication in these cells compared to Vero cells. Vero cells were cultured in medium 199, containing 5% fetal bovine serum (FBS) and 0.1% sodium bicarbonate, whereas MA-104 and C127I cells were grown in Eagle's medium (MEM) containing 10% FBS and 0.1% bicarbonate. MEM containing 2% FBS, 0.18% bicarbonate, and 50 µg/ml gentamicin was used for viral propagation and assays. This medium adequately sustains cell viability of the three cell lines in stationary monolayers during viral assays.
Development and isolation of a cidofovir-resistant (CDV-R) virus
The CDV-R form of the virus was developed by replicating the virus in the presence of increasing concentrations of drug. This entailed using a virus titre at each virus passage of about 400 plaque forming units (PFU) per well in 12-well microplates containing monolayers of Vero cells. Thus, determination of virus production at each step was necessary to provide a consistent viral challenge from passage to passage. Cultures were usually incubated for 6 days, although the wells left untreated exhibited 100% cytopathology in 3 days (and were harvested at that time). The starting concentration of cidofovir in the selection process was 50 µM, which was approximately the 50% virus-inhibitory concentration determined against the WT virus. Three concentrations of drug were used at each successive passage, and the highest concentration where virus was able to replicate (as evidenced by plaque formation and expansion) was selected for the next passage. After development of drug resistance (replication in 1 mM cidofovir), the final virus preparations were twice plaquepurified by dilution to extinction in 96-well plates in the absence of drug. Drug sensitivity assays were run on 5-10 virus isolates per plaque purification step to select the resistant virus for later use. The entire process required 15 virus passages in cell culture, 13 of which used drug for selective pressure. A WT virus was propagated in parallel for 15 passages. This was designated WTp15 virus. Low passage WT virus (the original starting virus passage) was compared with the other two viruses in the various assays.
Plaque and virus yield reduction assays
Sensitivities of the WT, WTp15, and CDV-R, viruses to selected antiviral compounds were determined in 12-well plates of Vero cells. Plates of cells were infected with about 75-100 plaque forming units (PFU) of virus per well, virus was adsorbed for 0.5-1 h, then twofold dilutions of antiviral compounds were applied for 3 days. Cells were fixed and stained in 10% buffered formalin containing 0.2% crystal violet for 15 min, the aspirated plates were rinsed with water and plaque numbers were determined. Concentrations of compounds reducing plaque numbers by 50% (EC 50 values) were determined by plotting percent reduction versus inhibitor concentration on a semi-log 10 graph.
To determine the effect of cidofovir on WT and CDV-R virus production in Vero cells, virus yield assays were conducted. Twelve-well plates of cells were infected with vaccinia virus at about 200 PFU/well. After virus adsorption, the cells were fed maintenance medium with or without drug. On day 3 the infected cells were frozen, thawed and sonicated for 30 sec. Subsequently, the medium (representing both intracellular and extracellular virus produced during the infection) was titrated by plaque assay on new monolayers of Vero cells. After 3 days, the cells were fixed and stained, and plaques were counted.
A similar assay was used to compare replication of WT and CDV-R viruses in Vero and C127I cells in the absence of drug. Higher concentrations of virus stocks were required to achieve 200 PFU/well in C127I cells compared to Vero cells, based upon the different plaquing efficiencies of the two cell types.
Mouse experiments
Immune-competent female, specific pathogen-free BALB/c mice weighing 13-15 g and severe combined immunodeficient (SCID) mice weighing about 20 g each were obtained from Charles River Labs (Wilmington, MA, USA). Both strains of mouse were used to assess virulence of the CDV-R virus. Later, only the BALB/c mice were used in antiviral studies to determine the efficacies of known-active vaccinia virus inhibitors.
Mice were infected intranasally with 0.05 ml of WT or CDV-R viruses following anaesthesia with ketamine (100 mg/kg, by ip injection). Virus was given in 3.2-fold (halflog 10 ) dilution increments to groups of BALB/c mice, with the highest dose being 10 7 PFU of the CDV-R virus. Mice were held until death or for 21 days. No tissues were taken from the animals for these initial lethality determinations. In a subsequent experiment, snout and lung virus titres were assayed over several days to determine the extent of virus replication in these tissues. Virus titres were sufficiently high to study reductions in tissue virus titres during chemotherapy. Since none of the BALB/c mice died from infection with the CDV-R virus, infection in SCID mice was studied. These mice have been shown to be highly sensitive to lethal infection with WT vaccinia virus (Neyts & De Clercq, 1993) . Lethality determinations in SCID mice were made with an intranasal challenge dose of 10 7 PFU of CDV-R virus. Because none of these mice died, various tissues were taken from the SCID mice on day 30 of the infection for virus titre determinations.
Antiviral experiments with the CDV-R virus were performed in the non-lethal BALB/c mouse model by assessing infectious parameters in lungs and snouts. The animals were challenged intranasally with 5×10 6 PFU of CDV-R virus. Treatments with compounds were given by ip injection or po starting 1 day after virus exposure. The treatment schedules and doses of antiviral compounds that were used for the experiments were based upon our previous work (Smee et al., 2001a (Smee et al., , 2002a .
Tissues for virus titre determinations were harvested, weighed, and frozen at -80°C. Later, thawed tissues were homogenized, using sterile mortars and pestles for snouts or in stomacher bags for lungs, in 1 ml of cell culture medium; the homogenates were then frozen. On the day of titration, thawed homogenates were sonicated 30 sec each and centrifuged at 600× gravity for 5 min. The samples were serially diluted in 10-fold increments and plaque titrated in 12-well plates of Vero cells. Plaque numbers were determined after 3 days following fixing and crystal violet staining (Smee et al., 2001a) . Virus titres were reported as log 10 PFU per gramme of tissue.
Statistical interpretations
Reductions in mean tissue virus titres, lung scores, and lung weights were statistically analysed by the two-tailed MannWhitney U-test using the InStat computer program (GraphPad Software, San Diego, CA, USA). Other parameters (death and mean day of death) could not be analysed because infections with the CDV-R virus were not lethal.
Results
Several anti-orthopoxvirus agents were tested for their ability to inhibit WT and CDV-R forms of vaccinia (WR strain) virus in Vero cell culture (Table 1) . Slight (less than twofold) differences were seen in the sensitivity of compounds against the WT virus and the WTp15 virus. The CDV-R virus was 13-to 14-fold more resistant to cidofovir than the two forms of WT virus. Similar degrees of cross resistance were seen with HPMPA and HDPcidofovir. A 5-7 fold decrease in potency of HPMPG was seen against the CDV-R virus. The chemically unrelated compounds Ara-A, ribavirin, and S2242 were similarly active against the CDV-R and the two WT vaccinia viruses in cell culture (Table 1) .
A comparison was made of the effects of cidofovir on vaccinia virus yield from Vero cells (Figure 1) . The downward slopes of the dose-response curves against the three viruses were similar. The WTp15 virus was slightly more sensitive to inhibition by cidofovir than was the WT virus. In these assays, cidofovir concentrations inhibiting virus yield by 90% (one log 10 ) were 35, 15 and 320 µM against WT, WTp15 and CDV-R viruses, respectively. Thus, only at high cidofovir concentrations was there any appreciable inhibition of CDV-R virus production.
One of the observations made in a former publication was that cidofovir-resistant orthopoxviruses may exhibit differential growth characteristics in monkey versus mouse cells (Smee et al., 2002b) . This effect could translate into reduced virulence of the resistant viruses in mice. We already knew that a higher vaccinia virus titre was required to infect mouse cells compared to monkey cells (that is, titration of a virus pool in both types of cells indicated 10-fold or higher detectable PFU in monkey cells than in mouse cells). Using equivalent virus infectious doses, virus yields from African green monkey kidney (Vero) cells were compared to yields from C127I mouse mammary tumour cells in three independent assays. Virus titres produced over 3 days in Vero cells for WT, WTp15 and CDV-R viruses were 7.5 ±0.1, 7.5 ±0.3 and 7.1 ±0.3 log 10 PFU/ml, respectively. Corresponding titres produced in C127I cells were 7.2 ±0.1, 7.3 ±0.2 and 4.7 ±0.5 log 10 PFU/ml, respectively. Thus, the WT and WTp15 viruses showed similar replication characteristics in the two cell lines. However, the CDV-R virus produced over 300-fold less virus in mouse cells compared to monkey kidney cells (a statistically significant difference of P<0.001).
It was previously demonstrated that two forms of CDV-R cowpox virus exhibited decreased virulence properties in mice (Smee et al., 2002b) . Because of the highly virulent nature of the WT vaccinia (WR strain) virus in these animals (Smee et al., 2001a,b) , it was hypothesized that DF Smee et al. 206 ©2005 International Medical Press even with some attenuation of virulence the CDV-R form of this vaccinia virus strain would retain its lethal properties. To test this hypothesis, lethality titrations were conducted in mice using WT, WTp15, and CDV-R vaccinia viruses (Table 2 ). The WT virus was highly virulent and caused 100% mortality at an infectious dose of 10 4.5 PFU per animal. The WTp15 virus exhibited attenuation in vivo, and was 100% lethal at a 100-fold higher concentration. The CDV-R virus was completely nonlethal at the highest concentration tested, which was at least 1000-fold higher than the WT virus minimum lethal dose (10 4 PFU) tested in mice. Cyclophosphamide was used in an attempt to enhance lethality during the WTp15 and CDV-R virus infections (Table 2 ). In each case immunosuppression with cyclophosphamide did not lead to a substantial increase in mortality.
Severe combined immunodeficient (SCID) mice are much more susceptible to cowpox and vaccinia virus infections than normal mice (Neyts & De Clercq, 1993; Smee et al., 2002b) . If the CDV-R vaccinia (WR strain) virus possessed any degree of virulence, it would induce a progressive infection in these animals. Eight SCID mice were infected intranasally with the CDV-R virus at 10 7 PFU per animal; they were then observed for 30 days. None of the animals died or lost weight; thus, it was decided to sacrifice them and titrate tissues for virus. No detectable virus was recovered from liver, spleen or kidney. Lung and brain tissues had 2000 and 1600 PFU/g, respectively, which represented very low virus titres. The results indicate the extreme attenuation of the CDV-R vaccinia virus in mice.
One of the main purposes of this research was to develop an animal model to study the treatment of CDV-R vaccinia virus with antiviral agents. The data indicated that we did not have a lethal infection model. Other unrelated but scientifically useful virus infections are also nonlethal, such as respiratory syncytial virus and SARS coronavirus infections in rodents (Enserink, 2003; Cianci et al., 2004) . In these non-lethal models, tissue virus titre reductions are used as an indication of antiviral activity. With the CDV-R virus infection, it was important to determine if sufficient tissue virus titres would develop during the infection to show sufficient decreases during antiviral therapy. Thus, BALB/c mice were exposed to 5×10 6 PFU of the CDV-R vaccinia virus, and lung and snout tissues were examined for virus titre on days 2, 4 or 6 after infection. Cyclophosphamide was administered to some animals to determine if immunosuppression would enhance virus production. In normal mice, recovered virus titres from lungs and snouts were about 10 4 -10 5 PFU/g on days 2 and 4 (peaking on day 4), with a decline in titre seen on day 6. Some lung consolidation was also observed, but lung weights were normal. Cyclophosphamide treatment did not enhance virus titre production or affect lung consolidation scores. It appeared from these data that antiviral activity could be assessed using lung and snout virus titre reduction parameters in normal mice, as well as determination of the extent of lung consolidation. But there appeared to be no advantage to using mice immunosuppressed with cyclophosphamide.
Based upon the above observations, an antiviral study was conducted using five antiviral agents against the CDV-R virus infection in BALB/c mice by assessing tissue virus titres and determining lung consolidation scores and lung weights, on day 4 of the infection (Table 3) . Lungs and snouts from five mice/group (experiment 1 of Table 3 ) or seven animals/group (experiment 2 of Table 3) were collected from sacrificed mice on day 4 for tissue virus titre determinations. Lung consolidation scores (rated on a scale from 0 to 4) and lung weights were also determined, as was reported previously for WT vaccinia virus (Smee et al., 2001a,b) . Lung virus titres did not decrease even fourfold by antiviral treatment although, because sample variation was small, most of the treatments reduced lung virus titres significantly. A larger difference between treated and placebo groups was seen with snout virus titres. Treatment with cidofovir reduced snout virus titres over 300-fold. Lesser, but statistically significant, reductions in snout virus titre were seen in groups treated with Ara-A, HDP-cidofovir and HOE961 (the orally active diacetate ester prodrug form of S2242). Cidofovir and HDP-cidofovir caused the greatest improvement in lung consolidation scores relative to the placebo group. HOE961 and ribavirin also provided some benefit in reducing lung consolidation. Lung weights were not elevated by the infection; thus, no effect of treatment was seen.
A follow-up animal study was conducted using cidofovir at three doses to treat the CDV-R virus infection (Table 3 , experiment 2). Virus titres in the placebo group were about fivefold less (for lungs) and eightfold less (for snouts) than was seen in the first experiment. Less lung virus titre production may have contributed to lower lung consolidation scores in the second study. The 100 mg/kg/day dose of cidofovir reduced lung virus titres to about the same extent as in experiment 1, although the results were not statistically significant due to greater variability in the placebo group. Snout virus titres were reduced eightfold by the 100 mg/kg/day treatment; this was statistically significant. The reduction in snout virus titre was not as dramatic as was seen in the first experiment. The 50 and 25 mg/kg/day doses were not effective in reducing lung and snout virus titres. Treatment with cidofovir did not reduce lung consolidation scores at any dose of drug compared to the placebo group, which differed from the results of the first experiment. Lung weights were normal among all groups, thus no drug effect was seen.
Discussion
The results demonstrate that a CDV-R vaccinia virus was cross-resistant to structurally related antiviral compounds (HPMPA, HDP-cidofovir, and HPMPG) but not to unrelated inhibitors (ara-A, ribavirin, and S2242) in cell culture. Previously we showed that a CDV-R vaccinia (Copenhagen strain) virus was not cross-resistant to HPMPA; however, CDV-R camelpox, cowpox, and monkeypox viruses exhibited cross-resistance to this compounds (Smee et al., 2002b) . The vaccinia virus DNA polymerase is the likely target for the majority of the compounds tested, and the site of mutation, based upon the published mode of action of cidofovir against cowpox virus (Smee et al., 2002b) , herpes simplex virus (Ho et al., 1992; Andrei et al., 2000) and cytomegalovirus (Chou et al., 2000) . Gene sequencing of the CDV-R vaccinia virus is in progress and will be reported elsewhere. The results presented here suggest that the mutation of the CDV-R vaccinia (WR strain) virus DNA polymerase may not be identical to that of the CDV-R vaccinia (Copenhagen strain) virus because of their differential sensitivities to HPMPA. HDP-cidofovir and HPMPG were not tested previously against the other CDV-R orthopoxviruses. Because the virus is resistant to both purine (HPMPA, HPMPG) and pyrimidine (cidofovir) analogues, this suggests that the resistance may be due to poor interaction of the acyclic phosphonyl side chain to the viral DNA polymerase. S2242 is an acyclic adenine-like compound lacking the phosphonate group, but possessing a normal triphosphate group in its activated form (Neyts et al., 1998) . S2242 has been shown to inhibit cytomegalovirus DNA synthesis (Neyts et al., 1994) . Ara-A possesses a 2′-arabinofuranosyl moiety that is closely related to the natural substrate for DNA synthesis, 2′-deoxyadenosine. Ara-A acts via inhibition of viral DNA polymerases (Coen et al., 1982) . Ribavirin showed a similar pattern of activity against WT and CDV-R vaccinia (WR strain) viruses, as it did against other poxviruses (Smee et al., 2002b) . Its mode of antiviral action does not require viral DNA polymerase; instead, it involves nucleotide pool depletion via the inhibition of cellular inosine monophosphate dehydrogenase (Streeter et al., 1973; Smee 2001c) as well as inhibition of vaccinia virus mRNA capping (Goswami et al., 1979) .
A high concentration of cidofovir was required to inhibit CDV-R virus plaque formation and virus yield in Vero cells. The potency of the compound against poxviruses in mouse cells is much greater than in monkey cells (Smee et al., 2001c) , which most likely translates into a benefit to the animals during treatment of the infection. We demonstrated here with vaccinia virus and elsewhere with cowpox and monkeypox viruses (Smee et al., 2002b) that the CDV-R virus replicated poorly in mouse cells compared to replication in African green monkey kidney cells. The reason why this occurred is not known, although it is possible that selection for replication in Vero cells (after extensive passages) may have caused deletion of genetic information important for replication in mouse cells. It may also be that cidofovir resistance and host range changes are a result of the same genetic mutation.
Complete attenuation of the CDV-R virus was seen in normal BALB/c and in SCID mice. SCID mice are highly susceptible to WT cowpox and vaccinia virus infections, and ultimately die even from very low virus challenge doses (Neyts et al., 1993; Smee et al., 2002b) . In the present experiment a very high virus challenge dose was administered to SCID mice with no deleterious consequences. In order to be lethal to SCID mice, the viruses must possess at least some degree of virulence. The results reported here illustrate the extreme degree of attenuation of the CDV-R virus, since the virus did not even induce weight loss during the first week of the infection. The poor ability of the CDV-R virus to replicate in mouse cells may partly explain the attenuation of virulence of the virus in mice. Another factor contributing to loss of virulence occurred during extensive cell culture passage of virus in Vero cells, as was evident in the WTp15 virus (and probably occurred in the CDV-R virus). A virulence gene important for efficient replication in vivo but not in vitro may have been lost due to mutation during cell culture passage. Because of the large number of genes present in the viral genome, it may be difficult to identify the mutated gene(s) responsible for cell culture-induced attenuation. Initially, we hypothesized that the virus would retain its ability to kill mice (although requiring a higher infectious dose) because firstly, the original WT virus was so highly virulent to the animals and secondly, this was successfully accomplished with a CDV-R form of cowpox virus (Smee et al., 2002b) . However, this proved to not be the case.
Because of the non-lethal nature of the CDV-R vaccinia (WR strain) virus in mice, antiviral experiments could only be conducted in vivo by studying effects of antiviral treatment on lung and snout virus titres, and on lung consolidation scores. It was interesting that, of five antiviral agents tested in mice, cidofovir emerged as the most active against the CDV-R virus. The method of treatment with cidofovir was to give a large bolus injection. Treatment with the other compounds was given using high doses found active in previous experiments (Smee et al., 2001a (Smee et al., , 2002a . In other animal studies with pox viruses, cidofovir has consistently emerged as the most active compound, probably because of the long-term persistence of the active form, cidofovir diphosphate, inside of cells (Ho et al., 1992) . The related compounds, HPMPA and HPMPG, may share similar metabolic properties with cidofovir, but such determinations have not been reported. To date, HPMPA and HPMPG have not been evaluated in lethal animal infections with vaccinia or cowpox viruses to assess their utility, primarily due to the lack of sufficient quantities of compound for testing.
The CDV-R virus infection animal model is limited because of its non-lethal nature and restricted number of parameters that can be evaluated. Variability occurred in the amount of virus recovered from lungs and snouts and extent of lung consolidation between the two experiments reported here. Snout virus titre reduction with cidofovir treatment (300-fold) seen in mouse experiment 1 was probably the extreme of what may generally occur (a 16-fold decrease during treatment was seen in experiment 2). This conclusion is partly based upon results with WT virus
